{
    "nctId": "NCT06575049",
    "briefTitle": "Seroma and Hematoma Rates: MAXIGESIC IV vs. Ketorolac in Breast Cancer Surgery",
    "officialTitle": "Comparative Analysis of Seroma and Hematoma Rates: MAXIGESIC vs. Ketorolac in Breast Cancer Surgery Patients",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer, Post-Operative Hematoma, Seroma as Procedural Complication, Post-Op Complication",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Postoperative hemovac or JP total drainage amount",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Systemic performance status 0-2 according to ECOG criteria\n* Patients with adequate renal function: serum Cr 1.4 mg/dL or less\n* Patients with adequate liver function Bilirubin, AST/ALT: 1.5 times or less of the upper limit of normal, Alkaline phosphatase: 1.8 times or less of the upper limit of normal\n* Patients undergoing total mastectomy with SLNB or ALND (mastectomy and axillary sentinel lymph node dissection)\n* Patients undergoing breast-conserving surgery with ALND (mastectomy and axillary dissection)\n* Patients who voluntarily decided to participate in this study and signed a written informed consent form\n\nExclusion Criteria:\n\n* Patients undergoing immediate reconstruction operation\n* Patients with drug allergies to painkillers and anti-inflammatory drugs\n* Patients with a physical condition that would interfere with understanding and submitting the consent form",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}